WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318352
CAS#: 105816-04-4
Description: Nateglinide is a drug for the treatment of type 2 diabetes. Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Hodoodo Cat#: H318352
Name: Nateglinide
CAS#: 105816-04-4
Chemical Formula: C19H27NO3
Exact Mass: 317.20
Molecular Weight: 317.423
Elemental Analysis: C, 71.89; H, 8.57; N, 4.41; O, 15.12
Synonym: DJN 608; DJN-608l; DJN608; Nateglinide; Fastic; Starlix
IUPAC/Chemical Name: (R)-2-((1r,4R)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid
InChi Key: OELFLUMRDSZNSF-BRWVUGGUSA-N
InChi Code: InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1
SMILES Code: O=C(O)[C@@H](CC1=CC=CC=C1)NC([C@H]2CC[C@H](C(C)C)CC2)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 317.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Campbell IW. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus. Int J Clin Pract. 2005 Oct;59(10):1218-28. Review. PubMed PMID: 16178991.
2: Phillips LS, Dunning BE. Nateglinide (Starlix): update on a new antidiabetic agent. Int J Clin Pract. 2003 Jul-Aug;57(6):535-41. Review. PubMed PMID: 12918894.
3: Tentolouris N, Voulgari C, Katsilambros N. A review of nateglinide in the management of patients with type 2 diabetes. Vasc Health Risk Manag. 2007;3(6):797-807. Review. PubMed PMID: 18200800; PubMed Central PMCID: PMC2350129.
4: Israel MK, Istvan E, Baron MA. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes. Vasc Health Risk Manag. 2008;4(6):1167-78. Review. PubMed PMID: 19337530; PubMed Central PMCID: PMC2663444.
5: Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108. Review. PubMed PMID: 17253883.